Korea Exchange · Healthcare
Yuyu Pharma stock from India: price, numbers and tax
Yuyu Pharma (000220) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Yuyu Pharma at a glance
- Price
- ₩3,840.00+₩0.00 (0.00%)
- Market cap
- ₩60.47B
- Day range
- ₩3,795.00 – ₩3,870.00
- P/E
- 5.14
- Dividend yield
- 2.99%
- Volume
- 46.22K
- 1 month
- -0.39%
- 6 months
- -8.90%
- YTD
- -14.95%
- 1 year
- -10.90%
- 5 years
- -46.89%
Yuyu Pharma statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩140.9B | ₩133.1B | ₩137.2B | ₩138.9B | ₩115.7B |
| Gross profit | ₩53.9B | ₩51.7B | ₩48.5B | ₩53.3B | ₩45.3B |
| Operating income | ₩11.0B | ₩11.7B | ₩364.5M | ₩691.7M | ₩2.7B |
| Net income | ₩8.2B | ₩8.7B | −₩7.2B | −₩4.4B | −₩920.3M |
| Earnings per share | ₩492.00 | ₩468.10 | −₩441.41 | −₩266.90 | −₩57.67 |
| EBITDA | ₩16.6B | ₩18.9B | ₩4.9B | ₩3.4B | ₩6.3B |
| Total assets | ₩207.2B | ₩207.7B | ₩198.2B | ₩195.2B | ₩193.0B |
| Total debt | ₩27.9B | ₩33.6B | ₩39.4B | ₩39.3B | ₩39.2B |
| Cash and short-term investments | ₩29.1B | ₩42.6B | ₩32.4B | ₩30.8B | ₩50.3B |
| Shareholders' equity | ₩129.3B | ₩125.2B | ₩112.2B | ₩116.8B | ₩124.3B |
| Operating cash flow | ₩16.1B | ₩25.0B | ₩420.9M | −₩6.2B | ₩4.5B |
| Free cash flow | ₩7.8B | ₩17.6B | −₩4.7B | −₩11.8B | −₩2.2B |
| Capital expenditure | −₩8.3B | −₩7.3B | −₩5.1B | −₩5.6B | −₩6.8B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Hyundai Pharmaceutical | 004310.KS | ₩7,760.00 | ₩181.97B |
| KUKJE PHARMA | 002720.KS | ₩4,270.00 | ₩90.35B |
| Enzychem Lifesciences | 183490.KQ | ₩990.00 | ₩83.79B |
| Ildong | 000230.KS | ₩6,160.00 | ₩71.09B |
| PharmGen Science | 004720.KS | ₩2,860.00 | ₩62.67B |
| ORIENT BIO | 002630.KS | ₩1,638.00 | ₩48.56B |
| MYUNGMOON Pharm | 017180.KS | ₩1,286.00 | ₩42.99B |
| LAMEDITECH | 462510.KQ | ₩3,505.00 | ₩30.85B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Yuyu Pharma from India
What Yuyu Pharma does
Yuyu Pharma, Inc. specializes in the development and commercialization of pharmaceutical products. Its extensive portfolio of prescription medications addresses a wide range of conditions, including osteoporosis, disorders related to brain-bone metabolism and hypocalcemia, cerebral and peripheral circulatory issues, thromboembolic events, respiratory ailments, hypertension, pulmonary tuberculosis, joint inflammation (arthrifuge), diabetic neuropathy, and eczematous dermatitis. Yuyu Pharma operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Yuyu Pharma shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.